Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SGMS1 | Q86VZ5 | 4/20 | 0.43 |
| ▸ | SGMS2 | Q8NHU3 | 4/20 | 0.43 |
| ▸ | YAP1 | P46937 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12847385 | 0.86 | ACHE (0.43) | — | |
| SCHEMBL12788962 | 0.80 | MEN1 (0.45) | GPR119 | |
| SCHEMBL12789518 | 0.79 | HTT (0.41) | PDE3BPDE3A | |
| SCHEMBL12788473 | 0.77 | ACHE (0.43) | PDE3BPDE3A | |
| SCHEMBL12788957 | 0.76 | MEN1 (0.45) | GPR119 | |
| SCHEMBL12788964 | 0.75 | PDK2 (0.44) | GPR119 | |
| SCHEMBL13249889 | 0.75 | KDM4E (0.41) | GPR119 | |
| SCHEMBL12789075 | 0.75 | DRD2 (0.43) | — | |
| SCHEMBL13329327 | 0.74 | KDM4E (0.42) | GPR119 | |
| SCHEMBL12788465 | 0.74 | SMN1; SMN2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | MERCK SHARP & DOHME CORP. | 2011-03-17 | — | — | US | disclosed |
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | MERCK SHARP & DOHME CORP. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | GPR119, GPR39, GPR65 | GPR119 1/4885CHEK2 3460/4885CSF1R 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.